Skip to main content

Table 2 Injection-site reaction in the STAR trial

From: Does safety make a difference in selecting the right TNF antagonist?

  Patients (%)  
Event Adalimumab + SOC (n = 318) Placebo + SOC (n = 318) P
Injection-site reaction 19.5 11.6 <0.05
  1. More than one occurrence per patient is possible. Injection-site reactions were the most frequent reported non-infection adverse event. Data on file, Abbott Laboratories, Abbott Park, IL, USA. STAR, Safety Trial of Adalimumab in Rheumatoid Arthritis; SOC, standard of care.